Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway - PubMed (original) (raw)
. 2014 Jan 1;134(1):43-54.
doi: 10.1002/ijc.28341. Epub 2013 Aug 5.
Affiliations
- PMID: 23784558
- DOI: 10.1002/ijc.28341
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway
Kaijie He et al. Int J Cancer. 2014.
Abstract
Cancer initiation and progression have been attributed to newly discovered subpopulations of self-renewing, highly tumorigenic, drug-resistant tumor cells termed cancer stem cells. Recently, we and others reported a new phenotypic plasticity wherein highly tumorigenic, drug-resistant cell populations could arise not only from pre-existing cancer stem-like populations but also from cancer cells lacking these properties. In the current study, we hypothesized that this newfound phenotypic plasticity may be mediated by PI3K/Akt and Wnt/β-catenin signaling, pathways previously implicated in carcinogenesis, pluripotency and drug resistance. Using GFP expression, Hoechst dye exclusion and fluorescence activated cell sorting (FACS) of cancer cell lines, we identified and tracked cancer stem-like side populations (SP) of cancer cells characterized by high tumorigenicity and drug resistance. We found that pharmacological inhibition or genetic depletion of PI3K and AKT markedly reduced the spontaneous conversion of nonside population (NSP) cells into cancer stem-like SP cells, whereas PI3K/Akt activation conversely enhanced NSP to SP conversion. PI3K/AKT signaling was mediated through downstream phosphorylation of GSK3β, which led to activation and accumulation of β-catenin. Accordingly, pharmacological or genetic perturbation of GSK3β or β-catenin dramatically impacted conversion of NSP to SP. Further downstream, β-catenin's effects on NSP-SP equilibrium were dependent upon its interaction with CBP, a KAT3 family coactivator. These studies provide a mechanistic model wherein PI3K/Akt/β-catenin/CBP signaling mediates phenotypic plasticity in and out of a drug-resistant, highly tumorigenic state. Therefore, targeting this pathway has unique potential for overcoming the therapy resistance and disease progression attributed to the cancer stem-like phenotype.
Keywords: PI3K/Akt; cancer stem-like cell; plasticity; side population; β-catenin/CBP.
© 2013 UICC.
Similar articles
- Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y, Berlind J, Mavila N. Tang Y, et al. Cell Commun Signal. 2018 Mar 12;16(1):9. doi: 10.1186/s12964-018-0222-5. Cell Commun Signal. 2018. PMID: 29530069 Free PMC article. - Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A, Alhoshani A, Korashy HM. Al-Dhfyan A, et al. Mol Cancer. 2017 Jan 19;16(1):14. doi: 10.1186/s12943-016-0570-y. Mol Cancer. 2017. PMID: 28103884 Free PMC article. - Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH, Du J. Wang H, et al. Eur J Pharmacol. 2014 Jan 15;723:156-66. doi: 10.1016/j.ejphar.2013.12.004. Epub 2013 Dec 12. Eur J Pharmacol. 2014. PMID: 24333218 - Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti A, Piazzi G, Alquati C, Ricciardiello L. Prossomariti A, et al. Cell Mol Gastroenterol Hepatol. 2020;10(3):491-506. doi: 10.1016/j.jcmgh.2020.04.007. Epub 2020 Apr 22. Cell Mol Gastroenterol Hepatol. 2020. PMID: 32334125 Free PMC article. Review. - PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways.
Lim SH, Lee H, Lee HJ, Kim K, Choi J, Han JM, Min DS. Lim SH, et al. Exp Mol Med. 2024 Jul;56(7):1479-1487. doi: 10.1038/s12276-024-01260-9. Epub 2024 Jul 1. Exp Mol Med. 2024. PMID: 38945955 Free PMC article. Review.
Cited by
- Effects of biomechanical forces on the biological behavior of cancer stem cells.
Tian BR, Lin WF, Zhang Y. Tian BR, et al. J Cancer. 2021 Aug 8;12(19):5895-5902. doi: 10.7150/jca.60893. eCollection 2021. J Cancer. 2021. PMID: 34476003 Free PMC article. Review. - miR-150 Suppresses the Proliferation and Tumorigenicity of Leukemia Stem Cells by Targeting the Nanog Signaling Pathway.
Xu DD, Zhou PJ, Wang Y, Zhang Y, Zhang R, Zhang L, Chen SH, Fu WY, Ruan BB, Xu HP, Hu CZ, Tian L, Qin JH, Wang S, Wang X, Liu QY, Ren Z, Gu XK, Li YH, Liu Z, Wang YF. Xu DD, et al. Front Pharmacol. 2016 Nov 18;7:439. doi: 10.3389/fphar.2016.00439. eCollection 2016. Front Pharmacol. 2016. PMID: 27917123 Free PMC article. - A novel lncRNA LNC_000052 leads to the dysfunction of osteoporotic BMSCs via the miR-96-5p-PIK3R1 axis.
Li M, Cong R, Yang L, Yang L, Zhang Y, Fu Q. Li M, et al. Cell Death Dis. 2020 Sep 23;11(9):795. doi: 10.1038/s41419-020-03006-7. Cell Death Dis. 2020. PMID: 32968049 Free PMC article. - The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway.
Cruz AF, Caleiras MB, Fonseca NA, Gonçalves N, Mendes VM, Sampaio SF, Moura V, Melo JB, Almeida RD, Manadas B, Simões S, Moreira JN. Cruz AF, et al. Cancers (Basel). 2021 Jun 18;13(12):3052. doi: 10.3390/cancers13123052. Cancers (Basel). 2021. PMID: 34207464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous